Inspire Medical Q3 revenue $109.2M (+77% YoY); raises FY2022 guidance to $384-388M

Inspire Medical Systems, Inc.

2022-Q3 EPS reported -$1.73 revenue$269,956,000

Revenue $109.2M (+77% YoY); raised FY2022 guidance to $384-388M from $354-362M.
Gross margin 81.9% (down from 86.0%) on inventory obsolescence and inflation; FY margin guidance maintained at 83-85%.
Net loss $16.8M ($0.60 diluted EPS) vs $10.3M ($0.38); cash $427.5M after $243.8M public offering.
Added 59 new U.S. centers (total 844) and 18 sales territories (total 209); launched Bluetooth remote and silicone leads.
European revenue down 14% on FX; France final pricing secured, reimbursement expected early 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 1.0

Inspire Medical Systems, Inc. reported quarter ended September 30, 2022 results: revenue $109.2 million. Guidance raised.

Period: quarter ended September 30, 2022
Revenue: $109.2 million
Guidance: raised
Result: reported results

Exact text from the filing

solutions for patients with obstructive sleep apnea, today reported financial results for the quarter ended September 30, 2022. Recent Business Highlights • Generated revenue of $109.2 million in the third quarter of 2022, a 77% increase over the same quarter last year • Achieved gross margin of 81.9% in the third quarter of 2022 • Activated 59 new centers in the U.S.

View on SEC.gov

Browse all earnings releases →

Inspire Medical Systems, Inc. filing history →

Source: SEC EDGAR

accession 0001609550-22-000047

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.